Malignancy and mortality in paediatric‐onset inflammatory bowel disease: a 3‐year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN

Alimentary Pharmacology & Therapeutics

Fecha de publicación: 08 July 2018

DOI: https://doi.org/10.1111/apt.14893

Autores: M. E. Joosse, M. A. Aardoom, P. Kemos, D. Turner, D. C. Wilson, S. Koletzko, J. Martin‐de‐Carpi, U. L. Fagerberg, C. Spray, C. Tzivinikos, M. Sladek, R. Shaoul, E. Roma‐Giannikou…

Background: Risk benefit strategies in managing inflammatory bowel diseases (IBD) are dependent upon understanding the risks of uncontrolled inflammation vs those of treatments. Malignancy and mortality in IBD have been associated with disease‐related inflammation and immune suppression, but data are limited due to their rare occurrence.